Abstract
Purpose :
To evaluate novel topical antimicrobial VBP-100 against multi-drug resistant biofilm forming pathogens.
Methods :
Biofilms of multi-drug resistant Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa and Candida albicans were developed on solid surfaces using the Calgary Biofilm Device (CBD) plate. Minimum biofilm eradication concentration (MBEC) was then determined for each test drug and for control samples of known antibiotics, ciprofloxacin and itraconazole
Results :
VBP-100 completely eliminated all biofilms of bacterial and fungal species in the test systems. Ciprofloxacin was able to eradicate one bacterial biofilm only at concentrations greater than 0.25 ug/mL.
Conclusions :
VBP-100 is a potent anti-bacterial and anti-fungal biofilm disrupting agent. Futher exploration in living systems is warranted.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.